Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer

Summary

Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.

Timeline

Start

2017-11-09

Primary completion

2022-11-04

Completion

2023-05-15

Drugs

Indications